Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FZ832
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on December 26, 2025, falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.99 billion master contract awarded on November 13, 2025. The delivery order represents a discrete purchase of pharmaceutical products and medical consumables to support Department of Defense healthcare operations, consistent with DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain. No set-aside designation was applied to this award, reflecting the contractor's competitive capability in unrestricted federal procurement.
DMS Pharmaceutical Group has demonstrated substantial performance across the PPV-G GEN V program, supplying a comprehensive range of products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare facilities. The contractor's product portfolio encompasses oncology treatments, immunosuppressants, emergency medications, specialty surgical products, contraceptives, vaccines, and routine pharmaceuticals. As a single-award regional prime vendor contractor under the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group holds a contract structure with a 30-month base period and three 30-month option periods extending through December 31, 2036, positioning the company to serve as a sustained pharmaceutical supplier for Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DU26FZ832?
SPE2DU26FZ832 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 26, 2025.
How much is contract SPE2DU26FZ832 worth?
The government has obligated $4,255 on SPE2DU26FZ832.
Is contract SPE2DU26FZ832 an order under another contract?
Yes. SPE2DU26FZ832 is a delivery order under SPE2DU25D9434, an indefinite delivery contract.
Was contract SPE2DU26FZ832 competed?
The extent of competition for SPE2DU26FZ832 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award